en · de · es · pt
thymosin-alpha-1-notes.peptides7501.com › Faq › Molecular Identity Of Thymosin Alpha-1 — Complete Guide

Molecular Identity Of Thymosin Alpha-1 — Complete Guide

By Editorial Desk · published 2025-10-16 · last reviewed 2025-12-06 · Faq

reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-12-06. Numbers and descriptions here follow the published literature rather than marketing material.

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Handling, Storage, and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.

Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.

Thymosin-alpha-1 at a glance

PropertyValueNotes
ClassSynthetic peptide28 residues; not a small-molecule compound
Molecular massAbout 3,106 DaMonoisotopic mass of the unmodified chain
N-terminal groupAcetylated serinePresent in both native and synthetic forms
Secondary structureDisulfide-constrained loopOne bridge between two cysteine residues
Typical sourceSolid-phase synthesisEarly isolates came from bovine thymus extracts

Research History and Clinical Assessment

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Related pages on this site

Storage Handling And Laboratory Analysis

Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.

The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.

Background and Mechanism of Action

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Supporting material

The isotopic compositions of ice cores from continental ice sheets and alpine glaciers have been developed as temperature proxies since the 1950s. Samuel Epstein was one of the first to show the applicability of this proxy by measuring oxygen isotopes in Antarctic snow, and also pointed out complications in the stable isotope-temperature correlation caused by the history of the air masses from which the snow formed. Ice cores in Greenland and Antarctica can be thousands of meters thick and record snow isotopic composition of the past few glacial-interglacial cycles. Ice cores can be dated by layer counting on the top and ice flow modeling at depth, with additional age constraints from volcanic ash. Cores from Greenland and Antarctica can be aligned in age at high-resolution by comparing globally well-mixed trace gas (e.g. CH4) concentrations in the air bubbles trapped in the cores. Some of the first ice core records from Greenland and Antarctica with age estimates go back to the last 105 years, and showed a depletion in δD and δ18O in the last ice age. The ice core record has since been extended to the last 800,000 years in Antarctica, and at least 250,000 years in Greenland. One of the best δD-based ice core temperature records is from the Vostok ice core in Antarctica, which goes back to 420,000 years. The δD-temperature (of the inversion layer where snow forms) conversion in east Antarctica based on modern spatial gradient of δD (9‰/°C) is ΔTI=(ΔδDice-8Δδ18Osw)/9, which takes into account variations in seawater isotopic composition caused by global ice volume changes.

== See also == Gomashio – a type of furikake mostly consisting of cooked black sesame seeds and sea salt crystals Ochazuke – a soup made by sprinkling seasonings (such as furikake) and toppings over cooked rice, then covering with brewed green tea Shichimi – a chilli-based spice mixture similar to furikake mainly used on noodles, soups and gyūdon List of sesame seed dishes Chutney

ÆON Albis Belc (ja) Costco Don Quijote - discount store Ito-Yokado Izumiya Kanesue Kansai Super Life Supermarket (ja) Maxvalu Tokai Seijo Ishii (ja) Seiyu Seiyu Group UNY Apita, Biago Yaokō, Kanto region, mainly Saitama Prefecture and Chiba Prefecture.

Peptidoglycan recognition protein 2 (PGLYRP2) is an enzyme (EC 3.5.1.28), N-acetylmuramoyl-L-alanine amidase (NAMLAA), that hydrolyzes bacterial cell wall peptidoglycan and is encoded by the PGLYRP2 gene.

Sources: en.wikipedia.org

Supporting material

==== United Kingdom ==== In the UK, A.G. Barr (the Scottish company that makes IRN BRU) and Ben Shaw's (a Cott brand), manufacture their own brands of cream soda, which are both clear and vanilla-flavoured. Some supermarket chains sell Cream Soda under their respective own brands. Pepsi has also introduced a cream soda flavoured drink.

=== University technology transfer === Despite the ethical, academic, commercial, and therapeutic controversies surrounding the identity and efficacy of "tethelin" itself (see below), Robertson's (1917) assignment of his tethelin patent to the University of California is universally treated as a landmark precedent event in the development of university technology transfer. In the ensuing years, the emergence of the concept of "intellectual property", driven by the theories and influence of Henri Bergson (the (August 1922) inaugural chairman of the League of Nations Committee on Intellectual Cooperation), made the already complex "paper vs. patent" issue even more fiercely contested, due to the significantly increased number of patents and the number of universities involved, and the extent to which a university's ever-increasing move towards commercialization not only reduced that institution's focus on the production of knowledge, but also privatised the knowledge that its researchers produced (PS.1):

=== Federal politics (2011–2025) === She was named the Conservative Party's candidate for Delta—Richmond East in March 2011, and won the seat in that year's federal election. During the 41st Parliament, she served as member of the House of Commons Standing Committee on Justice and Human Rights, and sat on a selection panel to help choose a replacement for Marie Deschamps of Quebec, who retired as puisne justice of the Supreme Court of Canada. She was named Parliamentary Secretary to the Minister of Justice in May 2011, and as Associate Minister of National Defence on February 22, 2013. She then served as the Minister of National Revenue from July 15, 2013, until November 4, 2015.

According to Time Magazine, self-poisoning is one of the leading methods of suicide attempts among adolescents, and has been identified as the third-leading cause of suicide-related deaths in this age group. A study published in the Journal of Pediatrics found that suicide attempts by poisoning among individuals under the age of 19 doubled between 2000 and 2018, increasing from nearly 40,000 cases to almost 80,000. During the COVID-19 lockdowns, reports indicated a 37% increase in cases of deliberate self-poisoning among adolescent girls. In biology, a poison is a chemical substance causing death, injury or harm to organisms or their parts. In medicine, poisons are a kind of toxin that are delivered passively, not actively. In industry the term may be negative, something to be removed to make a thing safe, or positive, an agent to limit unwanted pests. In ecological terms, poisons introduced into the environment can later cause unwanted effects elsewhere, or in other parts of the food chain.

During the Soviet period, apartments were lent to residents by the government according to a norm of square meters per person. Certain groups—including People's Artists, heroes, and prominent scientists—received bonuses proportional to their honors. Private ownership of apartments was limited until the 1990s, when residents were permitted to acquire rights to their inhabited properties. Since the Soviet era, apartment owners have needed to pay a service charge for their residences, a fixed amount based on residents per living area.

Sources: en.wikipedia.org

Supporting material

=== Transistors === Both chemically controlled and voltage controlled graphene transistors have been built. Graphene-based transistors could be much thinner than modern silicon devices, allowing faster and smaller configurations. Graphene exhibits a pronounced response to perpendicular external electric fields, potentially forming field-effect transistors (FET), but the absence of a band gap fundamentally limits its on-off conductance ratio to less than ~30 at room temperature. A 2006 paper proposed an all-graphene planar FET with side gates. Their devices showed changes of 2% at cryogenic temperatures. The first top-gated FET (on–off ratio of <2) was demonstrated in 2007. Graphene nanoribbons may prove generally capable of replacing silicon as a semiconductor. A patent for graphene-based electronics was issued in 2006. In 2008, researchers at MIT Lincoln Lab produced hundreds of transistors on a single chip and in 2009, very high frequency transistors were produced at Hughes Research Laboratories. A 2008 paper demonstrated a switching effect based on reversible chemical modification of the graphene layer that gives an on–off ratio of greater than six orders of magnitude. These reversible switches could potentially be employed in nonvolatile memories. IBM announced in December 2008 graphene transistors operating at GHz frequencies. In 2009, researchers demonstrated four different types of logic gates, each composed of a single graphene transistor. In May 2009, an n-type transistor complemented the prior p-type graphene transistors.

PD-L1, an immunosuppressive PD-1 ligand, is highly expressed in several cancers; the role of PD-1 in cancer immune evasion is well established. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. Inhibition of the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate preclinical antitumor activity. This is known as immune checkpoint blockade. PD-1 is expressed intrinsically in some tumor cells, such as melanoma, where it promotes tumor growth independently of the immune system. Inhibition of tumor cell-intrinsic PD-1 suppresses tumor growth, whereas overexpression or engagement by PD-L1 enhances tumorigenicity. Combination therapy using both anti-PD1 along with anti-CTLA4 therapeutics have emerged as important tumor treatments within the field of checkpoint inhibition. The effects of the two antibodies has been shown to be more effective than either antibody alone and does not appear to be redundant. Anti-CTLA4 treatment leads to an enhanced antigen specific T cell dependent immune reaction while anti-PD-1 appears to reactivate CD8+ T cells ability to lyse cancer cells. In clinical trials, combination therapy has been shown to be effective in reducing tumor size in patients that are unresponsive to single co-inhibitory blockade, despite increasing levels of toxicity due to anti-CTLA4 treatment. A combination of PD1 and CTLA4 induced up to a ten-fold higher number of CD8+ T cells that are actively infiltrating the tumor tissue.

=== Nerve fiber === The axons of nerve cells are surrounded by various connective tissue layers and bundled together in a structure called a nerve fiber. At the surface of a nerve fiber is a tissue layer called the epineurium or sometimes external epineurium. Within the epineurium there is a connective tissue matrix called the internal epineurium and fascicles. The internal epineurium acts as soft cushion for the fascicles. A nerve fiber may have a variable number of fascicles, but there will be at least one (otherwise there would be no nerve cells). Fascicles are surrounded by a tissue layer called the perineurium which is a protective sheath that acts as a barrier. Inside the fascicles is the endoneurium, a tissue matrix analogous to the internal epineurium, and the nerve cells. The endoneurium has many small blood capillaries (endoneurial microvessels) which directly supply the nerves themselves. These capillaries have tight junctions to prevent the free flow of materials between cells and instead require substances to pass through the endothelial cells.

As zolpidem is associated with drug tolerance and substance dependence, its prescription guidelines are only for severe insomnia and short periods of use at the lowest effective dose. Tolerance to the effects of zolpidem can develop in some people in just a few weeks. Abrupt withdrawal may cause delirium, seizures, or other adverse effects, especially if used for prolonged periods and at high doses. When drug tolerance and physical dependence to zolpidem develop, treatment usually entails a gradual dose reduction over a period of months to minimize withdrawal symptoms, which can resemble those seen during benzodiazepine withdrawal. Failing that, an alternative method may be necessary for some people, such as a switch to a benzodiazepine equivalent dose of a longer-acting benzodiazepine drug, as for diazepam or chlordiazepoxide, followed by a gradual reduction in dose of the long-acting benzodiazepine. In people who are difficult to treat, an inpatient flumazenil administration allows for rapid competitive binding of flumazenil to GABAA–receptor as an antagonist, thus stopping (and effectively detoxifying) zolpidem from being able to bind as an agonist on GABAA–receptor; slowly drug dependence or addiction to zolpidem will wane. Alcoholics or recovering alcoholics may be at increased risk of physical dependency or abuse of zolpidem. It is not typically prescribed to people with a history of alcoholism, recreational drug use, physical dependency, or psychological dependency on sedative-hypnotic drugs.

Fermentation is a type of anaerobic metabolism that harnesses the redox potential of the reactants to make adenosine triphosphate (ATP) and organic end products. Organic molecules, such as glucose or other sugars, are catabolized and their electrons are transferred to other organic molecules (cofactors, coenzymes, etc.). Anaerobic glycolysis is a related term used to describe the occurrence of fermentation in organisms (usually multicellular organisms such as animals) when aerobic respiration cannot keep up with the ATP demand, due to insufficient oxygen supply or anaerobic conditions. Fermentation is important in several areas of human society. Humans have used fermentation in the production and preservation of food for 13,000 years. It has been associated with health benefits, unique flavor profiles, and making products have better texture. Humans and their livestock also benefit from fermentation from the microbes in the gut that release end products that are subsequently used by the host for energy. Perhaps the most commonly known use for fermentation is at an industrial level to produce commodity chemicals, such as ethanol and lactate. Ethanol is used in a variety of alcoholic beverages (beers, wine, and spirits) while lactate can be neutralized to lactic acid and be used for food preservation, as a curing agent, or as a flavoring agent. This complex metabolism utilizes a wide variety of substrates and can form nearly 300 different combinations of end products. Fermentation occurs in both prokaryotes and eukaryotes.

Sources: en.wikipedia.org

Frequently asked questions

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Why is the disulfide bridge important?

The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.

How does it differ from other thymic peptides?

It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.

How should the dry powder be stored?

Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.

Network